Background: Available in-vitro and animal studies indicate that inflammation impacts
cytochromes P450 (CYP) activity via multiple and complex transcriptional and post …

Cytochrome P450 3A4 (CYP3A4), one of the most important members of the cytochrome
P450 subfamily, is a crucial catalyst in the metabolism of numerous drugs. As it catalyzes …

High interindividual variability (IIV) of the clinical response to epidermal growth factor
receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might …

Background Voriconazole is an antifungal drug used for the treatment of invasive fungal
infections. Due to highly variable drug exposure, therapeutic drug monitoring (TDM) has …

Typically, therapeutic proteins (TPs) have a low risk for eliciting meaningful drug interactions
(DIs). However, there are select instances where TP drug interactions (TP‐DIs) of clinical …

Drugs that modulate cytokine levels are often used for the treatment of cancer as well as
inflammatory or immunologic disorders. Pharmacokinetic drug-biologic interactions (DBIs) …

Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The
large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of …

Background: Voriconazole plasma concentration exhibits significant variability and
maintaining it within the therapeutic range is the key to enhancing its efficacy. We conducted …

The effects of inflammatory responses and polymorphisms of the genes encoding
cytochrome P450 (CYP)(CYP2C19 and CYP3A5), flavin‐containing monooxygenase 3 …

The magnitude of drug-drug interaction between tacrolimus and voriconazole is highly
variable, and individually tailoring the tacrolimus dose when concomitantly administered …